Open egonw opened 1 month ago
The case studies and regulatory questions have been added to the docs repo at this link. Please feel free to give feedback and let me know if we can close this issue.
Please add that p-gp is: P-glycoprotein 1 (permeability glycoprotein) also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of differentiation 243 (CD243) an important protein of the cell membrane that pumps many foreign substances out of cells (UniProt:P08183).
Note that 1) this explains why this is an important use case, 2) the many aliases, that are a result of how it was discovered, also pose a bioinformatics challenge, for which it would be good to document the solution.
I would not use "compound X" in two different use cases that relate to different compounds. Call them compound X and compound Y instead (for the two questions in use case 1 this is fine)
I think it would be OK to close this after you fix the above. But there should be follow-up questions we need to answer. 1) How do we make sure people can find this from the central pages. 2) where are the actual solutions and documented procedures, tools, workflows for each use case, 3) what is the procedure that was used to solve these use cases and what generic lessons for risk evaluation can be learned (how would you solve the next use case?) and where do we document that?
For the archives, the current screenshot:
I would not use "compound X" in two different use cases that relate to different compounds. Call them compound X and compound Y instead (for the two questions in use case 1 this is fine)
@Ozan, can you pick that up with the respective WP2.x's?
I've contacted the coordination team regarding this and they told me that they had forwarded it to the WP leaders.
The updates based on Chris and Jelle have been applied to the regulatory questions.
@ozancinar, the research questions can be found here: